Metraipolis › archive › dc_42bb27e2ef16

5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management — Europe PMC PMID:42195228

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42195228
DOI
10.3390/medicina62050975
License (as archived)
solo-consultazione
Archived
2026-11-02T05:43:19.382Z
SHA-256 of the archived text
c7509c5f3ffcb8aad2651f68096fc4776712e34e7772f8fa89bbc8ee05bab002
Stable URL of this page
https://metraipolis.com/documento/dc_42bb27e2ef16

How to cite

5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management — Europe PMC PMID:42195228 — Europe PMC (en), https://europepmc.org/article/MED/42195228 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_42bb27e2ef16 (Metraipolis archive dc_42bb27e2ef16, sha256 c7509c5f3ffcb8aad2651f68096fc4776712e34e7772f8fa89bbc8ee05bab002)
BibTeX
@misc{dc42bb27e2ef16,
  title = {5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management — Europe PMC PMID:42195228},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42195228},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_42bb27e2ef16; sha256 c7509c5f3ffcb8aad2651f68096fc4776712e34e7772f8fa89bbc8ee05bab002},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42195228. Agents can read the archived copy with the MCP tool read_document.